Express Mail Label No. EV339203016US
Date of Deposit: September 4, 2003
Attorney Reference Number 899-66834

Attorney Docket Number 899-66834 To be assigned 10/656701 **Application Number** Filed Herewith INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Gold 1647 Art Unit Examiner Name To be assigned NIC HOCK **U.S. PATENT DOCUMENTS** Cite No. Examiner' (optiona Number Date Name s Initials* 25 June 1991 5,026,381 Li 9 Mar 1993 5,192,773 Armistead et al. 5,330,993 19 July 1994 Armistead et al. 5,516,797 14 May 1996 Armistead et al. 5,525,523 11 June 1996 Soldin 5,543,423 6 Aug 1996 Zelle et al. 5,612,350 18 Mar 1997 Or et al. 5,614,547 25 Mar 1997 Hamilton et al. 5,620,971 15 Aug 1997 Armistead et al. 5,622,970 22 Apr 1997 Armistead et al. 5,639,592 17 June 1997 Evans et al. 5,654,332 5 Aug 1997 Armistead 5,780,484 14 July 1998 Zelle et al. 5,811,434 22 Sep 1998 Zelle et al. 24 Nov 1998 5,840,736 Zelle et al. 19 Oct 1999 5,968,921 Gold

EXAMINER SIGNATURE:	Glinks	DATE CONSIDERED:	719104

14 Mar 2000

Armistead

6,037,370

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		FOREIC	GN PATENT DOC	uments
Examiner' s Initials*	Cite No. (optional)	Number	Date	Country
3		WO 92/04370	19 Mar 1992	PCT
		WO 92/19593	12 Nov 1992	PCT
		WO 92/19745	12 Nov 1992	PCT
		WO 92/21313	10 Dec 1992	PCT
		WO 93/07269	15 Apr 1993	PCT
		WO 93/23548	25 Nov 1993	PCT
		WO 96/40140	19 Dec 1996	PCT
		WO 96/40633	19 Dec 1996	PCT
		WO 97/18828	29 May 1997	PCT
		WO 98/20891	22 May 1998	PCT
		WO 98/20892	22 May 1998	PCT
		WO 98/20893	22 May 1998	PCT
(2)		WO 99/21552	6 May 1999	PCT
Examiner' s Initials*	Cite No. (optional)	O'	THER DOCUMEN	TTS
<u>رهی</u>	·	Abstract, J. Biol. Chem.	, 252(1):308-317, 19	977.
		Abstract, Biochem., 31(9):2482-91, 1992.	
		Abstract, Mol. Endocrin	ol., 7(11):1418-29,	1993.
		Abstract, J. Clin. Investi	igation, 99(6):1217-	23, 1997.
		Armistead et al., Design FKBP12, the Major Bin D51:522-528 (1995).	, Synthesis and Stru ding Protein for the	cture of Non-macrocyclic Inhibitors of Immunosuppressant FK506, Acta Cryst
(2)		Bozzo et al., Exp. Cell R	Res., 214:313-22, 19	94.

EXAMINER SIGNATURE:	Sur	DATE CONSIDERED:	7/9/04	
A Francisco Taisi Vi	6			_

Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Reference Number 899-66834
9		Buttemeyer et al., Transpl. Proc., 27:1877-1878, 1995.
		Buttemeyer et al., Ann. Plast. Surg., 35:396-401, 1995.
*		Czar et al., Geldanamycin, a Heat Shock Protein 90-Binding Benzoquinone Ansamycin, Inhibits Steroid-Dependent Translocation of the Glucocorticoid Receptor from the Cytoplasm to the Nucleus, <i>Biochemistry</i> 36:7776-7785 (1997).
		David et al., Science, 214:931-33, 1991.
		Jackowski et al., Brit. J. Neurosurg., 9:303-317, 1995.
		Lee et al., Peripheral Nerve Injury and Repair, J. Am. Acad. Orthop. Surg., 8(4):243-252, 2000
		Miller et al., J. of Neurochemistry, 60:2134-44, 1993.
		Owens-Grillo et al., The Cyclosporin A-binding Immunophilin CyP-40 and the FK506-binding Immunophilin hsp56 Bind to a Common Site on hsp90 and Exist in Independent Cytosolic Heterocomplexes with the Untransformed Glucocorticoid Receptor, The Journal of Biological Chemistry 270:20479-20484 (1995).
		Owens-Grillo et al., Binding of Immunophilins to the 90 kDa Heat Shock Protein (hsp90) via a Tetratricopeptide Repeat Domain Is a Conserved Protein Interaction in Plants, Biochemistry 35:15249-15255 (1996).
		Pratt, W.B., The Role of the hsp90-based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling Via MAP Kinase, Annu. Rev. Pharmacol. Toxicol. 37:297-326 (1997).
		Pratt, W.B. and Toft, D.O., Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones, <i>Endocrine Reviews</i> 18:306-360 (1997).
		Preis et al., Cancer Res., 48:6530-34, 1988.
		Ratajczak, T. and Carrello, A. Cyclophilin 40 (CyP-40), Mapping of Its hsp90 Binding Domain and Evidence That FKBP52 Competes with CyP-40 for hsp90 Binding, <i>The Journal of Biological Chemistry</i> , 271:2961-2965 (1996).
		Sanchez, E.R. and Ning, Y-M., Immunophilins, Heat Shock Proteins, and Glucocorticoid Receptor Actions in Vivo, Methods 9:188-200 (1996).
(30)		Schawab, Repairing the Injured Spinal Cord, Science, 295:1029-1031, 8 Feb. 2002

EXAMINER SIGNATURE:		Niels	DATE CONSIDERED:	719/04
* Examiner: Initial in conformance ar	if reference	considered, whether or not sidered. Include copy of this	in conformance with M	IPEP 609. Draw line through cite if not

		 11-1012 of telefolio Number 677-00834
C3X	2	 Segnitz and Gehring, The Function of Steroid Hormone Receptors is Inhibited by the hsp90-specific Compound Geldanamycin, <i>The Journal of Biological Chemistry</i> 272:18694-18701 (1997).
·		Smith et al., Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent, Molecular and Cellular Biology 15:6804-6812 (1995).
		 Smith, Elements of Molec. Neurobio., 2 nd ed., p. 141-142. (1996)
		 Stancato et al., The hsp90-binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase, <i>The Journal of Biological Chemistry</i> 272:4013-4020 (1997).
		 Stebbins et al., Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent, Cell 89:239-250 (1997).
		 Tanzer L. and Jones K.J., Gonadal Steroid Regulation of Hamster Facial Nerve Regulation: Effects of Dihydrotestosterone and Estradiol, Experimental Neurology 146:258-264 (1997).
		 Wells et al., Exp. Neurol., 146:395-402, 1997.
V	7	 Whitesell et al., Cancer Res., 52:1721-28, 1992.
CZ	0	Whitesell et al., Inhibition of Heat Shock Protein HSP90-pp60 ^{v-sre} Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation, <i>Proc. Natl. Acad. Sci. USA</i> 91:8324-8328 (1994).

EXAMINER SIGNATURE: DATE CONSIDERED: 7/9/04

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.